UK Cancer Vaccines Market Size & Outlook, 2023-2030
UK cancer vaccines market, 2018-2030 (US$M)
Related Markets
UK cancer vaccines market highlights
- The UK cancer vaccines market generated a revenue of USD 349.1 million in 2023 and is expected to reach USD 666.3 million by 2030.
- The UK market is expected to grow at a CAGR of 9.7% from 2024 to 2030.
- In terms of segment, preventive cancer vaccines was the largest revenue generating vaccine type in 2023.
- Other Types is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Cancer vaccines market data book summary
| Market revenue in 2023 | USD 349.1 million |
| Market revenue in 2030 | USD 666.3 million |
| Growth rate | 9.7% (CAGR from 2023 to 2030) |
| Largest segment | Preventive cancer vaccines |
| Fastest growing segment | Other Types |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Other Types |
| Key market players worldwide | Merck & Co Inc, GSK PLC, Dynavax Technologies, Ferring, Amgen Inc, Moderna Inc, Sanofi SA, AstraZeneca PLC, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, UK accounted for 4.1% of the global cancer vaccines market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 983.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Vaccines Market Scope
Cancer Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cancer vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer vaccines market will help companies and investors design strategic landscapes.
Preventive cancer vaccines was the largest segment with a revenue share of 94.36% in 2023. Horizon Databook has segmented the UK cancer vaccines market based on preventive cancer vaccines, therapeutic cancer vaccines, other types covering the revenue growth of each sub-segment from 2018 to 2030.
- UK Cancer Vaccines Vaccine Type Outlook (Revenue, USD Million, 2018-2030)
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Other Types
- UK Cancer Vaccines Indication Type Outlook (Revenue, USD Million, 2018-2030)
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Cervical
- Other Indications
- UK Cancer Vaccines Technology Type Outlook (Revenue, USD Million, 2018-2030)
- Recombinant Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Other Technologies
Reasons to subscribe to UK cancer vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK cancer vaccines market databook
-
Our clientele includes a mix of cancer vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cancer vaccines market , including forecasts for subscribers. This country databook contains high-level insights into UK cancer vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK cancer vaccines market size, by vaccine type, 2018-2030 (US$M)
UK Cancer Vaccines Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
